Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.27 USD | +2.10% |
|
0.00% | +78.71% |
Jul. 17 | Oxford Biomedica Names New Finance Chief | MT |
Jul. 17 | K3 Business sees interim revenue decline | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+78.71% | 2.78B | - | ||
+24.74% | 47.96B | B- | ||
-0.47% | 42.45B | B | ||
+43.96% | 41.47B | A | ||
+25.40% | 31.6B | B | ||
+17.96% | 28.63B | B- | ||
-4.47% | 28.03B | C | ||
+50.73% | 14.56B | B+ | ||
+42.56% | 14.14B | C+ | ||
+1.46% | 12.58B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MOR Stock
- MPSYF Stock
- Ratings MorphoSys AG